Wednesday, November 09, 2022 1:14:35 PM
Thank you for bringing awareness to this topic. There are many articles commenting on the typical review timeline. Look them up. Here is an excerpt from one of those articles:
Everyone including the clinical investigators must wait for the independent peer review process to reach its conclusion. The whole reason why a peer-reviewed publication is so credible is because the company and researchers have nothing to do with it and cannot influence the timeframe determined by the reviewers.
The top peer-reviewed journal route was the best and most credible way to protect the validity of data, dispel disinformation, and facilitate truthful understanding and RA approval. Unfortunately, the journal is a double-edged sword—because it involves so many independent professionals, the company has no control and must surrender to their process. The silence and waiting is the price that was paid to preserve and protect the truth and validity of a unique landmark trial that would otherwise be further vulnerable to undue risk and bad-faith attacks.
Another interesting development to research was the redefinition of GBM during the time that the manuscript was written or just before that stage—research it. GBM was redefined during those months and the P3 was already an innovative trial of great complexity with data from 94 sites worldwide.
Furthermore, the authors were working clinicians carrying out many professional duties during the height of the original pandemic when there was no vaccine and during Delta which disrupted every hospital.
https://virtualtrials.org/dcvax.cfm
Everyone including the clinical investigators must wait for the independent peer review process to reach its conclusion. The whole reason why a peer-reviewed publication is so credible is because the company and researchers have nothing to do with it and cannot influence the timeframe determined by the reviewers.
The top peer-reviewed journal route was the best and most credible way to protect the validity of data, dispel disinformation, and facilitate truthful understanding and RA approval. Unfortunately, the journal is a double-edged sword—because it involves so many independent professionals, the company has no control and must surrender to their process. The silence and waiting is the price that was paid to preserve and protect the truth and validity of a unique landmark trial that would otherwise be further vulnerable to undue risk and bad-faith attacks.
Another interesting development to research was the redefinition of GBM during the time that the manuscript was written or just before that stage—research it. GBM was redefined during those months and the P3 was already an innovative trial of great complexity with data from 94 sites worldwide.
Furthermore, the authors were working clinicians carrying out many professional duties during the height of the original pandemic when there was no vaccine and during Delta which disrupted every hospital.
https://virtualtrials.org/dcvax.cfm
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
